Page 82 - 80_04
P. 82
Efectos cardioprotectores de reducción de tamaño del infarto de miocardio…
41. Geyer H.; Caracciolo G.; Abe H.; Wilansky S.; Carerj S.; Gentile F.; Nesser HJ.; Khandheria B.;
Narula J.; Sengupta PP. Assessment of myocardial mechanics using speckle tracking
echocardiography, fundamentals and clinical applications. Journal of the American Society
of Echocardiography , official publication of the American Society of Echocardiography
23(4), 351-369, quiz 453-355 (2010).
42. Stanton T.; Leano R.; Marwick TH. Prediction of all-cause mortality from global
longitudinal speckle strain, comparison with ejection fraction and wall motion scoring.
Circulation. Cardiovascular imaging 2(5), 356-364 (2009).
43. Hung CL.; Verma A.; Uno H.; Shin SH.; Bourgoun M.; Hassanein AH.; McMurray JJ.;
Velazquez EJ.; Kober L.; Pfeffer MA.; Solomon SD.; investigators V. Longitudinal and
circumferential strain rate.; left ventricular remodeling.; and prognosis after myocardial
infarction. Journal of the American College of Cardiology 56(22), 1812-1822 (2010).
44. Konstam MA.; Kramer DG.; Patel AR.; Maron MS.; Udelson JE. Left ventricular remodeling
in heart failure, current concepts in clinical significance and assessment. JACC Cardiovasc
Imaging 4(1), 98-108 (2011).
45. Cohn JN.; Ferrari R.; Sharpe N. Cardiac remodeling--concepts and clinical implications, a
consensus paper from an international forum on cardiac remodeling. Behalf of an
International Forum on Cardiac Remodeling. Journal of the American College of Cardiology
35(3), 569-582 (2000).
46. White HD.; Norris RM.; Brown MA.; Brandt PW.; Whitlock RM.; Wild CJ. Left ventricular
end-systolic volume as the major determinant of survival after recovery from myocardial
infarction. Circulation 76(1), 44-51 (1987).
47. Migrino RQ.; Young JB.; Ellis SG.; White HD.; Lundergan CF.; Miller DP.; Granger CB.; Ross
AM.; Califf RM.; Topol EJ. End-systolic volume index is a strong predictor of early and late
mortality. The GUSTO-I Angiographic Investigators. Circulation 96(1), 116-121 (1997).
48. Verma A.; Meris A.; Skali H.; Ghali JK.; Arnold JM.; Bourgoun M.; Velazquez EJ.; McMurray
JJ.; Kober L.; Pfeffer MA.; Califf RM.; Solomon SD. Prognostic implications of left ventricular
mass and geometry following myocardial infarction, the VALIANT (VALsartan In Acute
myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging 1(5), 582-591
(2008).
49. van Berlo JH.; Maillet M.; Molkentin JD. Signaling effectors underlying pathologic growth
and remodeling of the heart. J Clin Invest 123(1), 37-45 (2013).
50. Haq S.; Choukroun G.; Lim H.; Tymitz KM.; del Monte F.; Gwathmey J.; Grazette L.; Michael
A.; Hajjar R.; Force T.; Molkentin JD. Differential activation of signal transduction pathways
in human hearts with hypertrophy versus advanced heart failure. Circulation 103(5), 670-
677 (2001).
51. Gonzalez A.; Ravassa S.; Beaumont J.; Lopez B.; Diez J. New targets to treat the structural
remodeling of the myocardium. J Am Coll Cardiol 58(18), 1833-1843 (2011).
52. Lymperopoulos A.; Rengo G.; Koch WJ. Adrenergic nervous system in heart failure,
pathophysiology and therapy. Circ Res 113(6), 739-753 (2013).
53. Francis GS.; Cohn JN.; Johnson G.; Rector TS.; Goldman S.; Simon A. Plasma
norepinephrine.; plasma renin activity.; and congestive heart failure. Relations to survival
and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Circulation. 87(6 Suppl), VI40-48 (1993).
54. Benedict CR.; Shelton B.; Johnstone DE.; Francis G.; Greenberg B.; Konstam M.; Probstfield
JL.; Yusuf S. Prognostic significance of plasma norepinephrine in patients with
asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation. 94(4), 690-
697 (1996).
55. Raake PW.; Schlegel P.; Ksienzyk J.; Reinkober J.; Barthelmes J.; Schinkel S.; Pleger S.; Mier
W.; Haberkorn U.; Koch WJ.; Katus HA.; Most P.; Muller OJ. AAV6.betaARKct cardiac gene
therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a
clinically relevant large animal heart failure model. Eur Heart J 34(19), 1437-1447 (2013).
56. Liu W.; Zi M.; Naumann R.; Ulm S.; Jin J.; Taglieri DM.; Prehar S.; Gui J.; Tsui H.; Xiao RP.;
Neyses L.; Solaro RJ.; Ke Y.; Cartwright EJ.; Lei M.; Wang X. Pak1 as a novel therapeutic
target for antihypertrophic treatment in the heart. Circulation 124(24), 2702-2715 (2011).
719
